Local and systhemic immunotherapy for bladder cancer: from bench to bedside

被引:0
|
作者
Carballido, Joaquin A. [1 ]
Vazquez Alba, David [1 ]
Rodriguez Monsalve, Maria [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Serv & Catedra Urol, Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2020年 / 73卷 / 10期
关键词
Transitional cell bladder carcinom; Immunology and bladder cancer; Immunotherapy; Bacillus Calmette-Guerin; BCG Mechanism of action; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL-CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; T1 PAPILLARY CARCINOMA; TUMOR-NECROSIS-FACTOR; HIGH-RISK TA; INTRAVESICAL BCG; UROTHELIAL CARCINOMA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic approaches for treatment of urothelial transitional cell carcinoma based on immune system modulation, as well as the contribution of introvesical Bacillus de Calmette-Guerin (BCG) and the recent incorporation of checkpoint inhibitors had found irrefutable proofs of concept for the indication of antitumoral immunontherapy in such tumors. Its extension and development at the present time covers all the locations of the wide spectrum of presentation and evolution of these tumors. Nowadays, apart for the low grade non muscle-invasive tumors, we are facing an unpredictable development of antitumoral immunotherapy in bladder cancer not only as an option in the primary treatment, but also in other scenarios such as non-responders when it comes to BCG, or the situation of ineligibility for systemic chemotherapy indication. The main objective of this review article is trying to translate the current basic mechanisms involved in different phases of transitional cell carcinomas antitumoral response, regardless of whether they are muscle-invasive or not, and to establish the rationale for their therapeutic intravesical or systemic administration. The role of the interactions established between urothelial tumor cells and the cellular and molecular elements of the immune system of patients is described, incorporating the relevant and recent advances in immunobiology and the molecular characterization of these tumors that will undoubtedly introduce far-reaching modifications in therapeutic regimes that will contrast with the traditional options available. Investigational lines that are already active in the clinical research phase with BCG and, checkpoints inhibitors of the immune response are also analyzed, highlighting the need to find predictive response markers as a real option for treatments personalization. The approach to the knowledge of the individual reactivity of the immune system of each patient as a determining factor to achieve it is proposed.
引用
收藏
页码:879 / 894
页数:16
相关论文
共 50 条
  • [31] Cancer Biomarkers from Bench to Bedside
    Gyoerffy, Balazs
    CURRENT CANCER DRUG TARGETS, 2015, 15 (08) : 642 - 642
  • [32] Cancer Therapy from Bench to Bedside
    Oh, William K.
    Burakoff, Steven J.
    MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (06): : 571 - 572
  • [33] Cancer research - From bench to bedside
    Izraeli, S
    Witz, I
    Micksche, M
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (09): : 746 - 748
  • [34] Externally-Controlled Systems for Immunotherapy: From Bench to Bedside
    Tristan-Manzano, Maria
    Justicia-Lirio, Pedro
    Maldonado-Perez, Noelia
    Cortijo-Gutierrez, Marina
    Benabdellah, Karim
    Martin, Francisco
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [35] Tumor immunotherapy with bispecific antibodies: From bench- to bedside
    Jung, G
    GrosseHovest, L
    Brandl, M
    Pfosser, A
    Wilmanns, W
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 89 - 89
  • [36] TIGIT: a novel immunotherapy target moving from bench to bedside
    Benjamin L. Solomon
    Ignacio Garrido-Laguna
    Cancer Immunology, Immunotherapy, 2018, 67 : 1659 - 1667
  • [37] TIGIT: a novel immunotherapy target moving from bench to bedside
    Solomon, Benjamin L.
    Garrido-Laguna, Ignacio
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (11) : 1659 - 1667
  • [38] Managing the impact of immunogenicity in an era of immunotherapy: from bench to bedside
    Bray-French, Katharine
    Hartman, Katharina
    Steiner, Guido
    Marban-Doran, CSeline
    Bessa, Juliana
    Campbell, Neil
    Martin-Facklam, Meret
    Stubenrauch, Kay-Gunnar
    Solier, Corinne
    Singer, Thomas
    Ducret, Axel
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (07) : 2575 - 2584
  • [39] Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
    Acebes-Fernandez, Vanessa
    Landeira-Vinuela, Alicia
    Juanes-Velasco, Pablo
    Hernandez, Angela-Patricia
    Otazo-Perez, Andrea
    Manzano-Roman, Raul
    Gongora, Rafael
    Fuentes, Manuel
    NANOMATERIALS, 2020, 10 (07) : 1 - 72
  • [40] Targeting gamma delta T cells for cancer immunotherapy: bench to bedside
    Gogoi, Dimpu
    Chiplunkar, Shubhada V.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2013, 138 : 755 - 761